SAN DIEGO, Nov. 11, 2010 /PRNewswire-FirstCall/ — Cadence
Pharmaceuticals, Inc. (Nasdaq:
CADX) today announced that it has priced an underwritten public
offering of 11,500,000 shares of its common stock at a price to the
public of $8.00 per share. The net proceeds from the sale of
the shares, after estimated underwriting discounts and commissions
and estimated offering expenses, are expected to be approximately
$86.2 million. The offering is expected to close on or about
November 16, 2010, subject to customary closing conditions. Cadence
has granted the underwriters for the offering an option for a
period of 30 days to purchase up to an additional 1,725,000 shares
of common stock to cover over-allotments, if any.
Deutsche Bank Securities Inc. is acting as sole book-running
manager for the offering. Leerink Swann LLC is acting as
co-lead manager, and JMP Securities, Wedbush PacGrow Life Sciences
and Canaccord Genuity Inc. are acting as co-managers for the
offering.The securities described above are being offered by
Cadence pursuant to shelf registration statements that have been
previously filed with and become effective by rule or order of the
Securities and Exchange Commission (the “SEC”). A preliminary
prospectus supplement related to the offering has been filed with
the SEC and is available on the SEC’s website at http://www.sec.gov.
Copies of the final prospectus supplement relating to these
securities, when available, may be obtained from Deutsche Bank
Securities Inc., Attn: Prospectus Department, 100 Plaza One, Floor
2, Jersey City, NJ 07311, Telephone number: (800) 503-4611, Email:
prospectusrequest@list.db.com. This press release shall
not constitute an offer to sell or the solicitation of an offer to
buy these securities, nor shall there be any sale of t
‘/>”/>
